AllianceBernstein
ATOS icon

AllianceBernstein’s Atossa Therapeutics ATOS Stock Holding History

AllianceBernstein’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,159
Closed -$11.7K – 3240
2025
Q1 		$11.7K Hold
1,159
– – ﹤0.01% 3190
2024
Q4 		$16.4K Hold
1,159
– – ﹤0.01% 3216
2024
Q3 		$26.4K Hold
1,159
– – ﹤0.01% 3214
2024
Q2 		$20.7K Buy
+1,159
New +$25.6K ﹤0.01% 3222
2022
Q2 		– Sell
-7,767
Closed -$146K – 3269
2022
Q1 		$146K Buy
7,767
+27
+0.3% +$549 ﹤0.01% 3060
2021
Q4 		$186K Hold
7,740
– – ﹤0.01% 3091
2021
Q3 		$378K Hold
7,740
– – ﹤0.01% 2868
2021
Q2 		$734K Buy
+7,740
New +$410K ﹤0.01% 2651

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein's ATOS Position: Q2 2025 in Review

AllianceBernstein sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 1,159 shares — an estimated $11.7K sold.

AllianceBernstein first reported a position in ATOS in Q2 2021 and held it in 8 quarters. The position peaked at $734K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • AllianceBernstein reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • AllianceBernstein sold 1,159 Atossa Therapeutics shares in Q2 2025, an estimated $11.7K.
  • AllianceBernstein first reported a position in Atossa Therapeutics in Q2 2021 and held it in 8 quarters.
  • AllianceBernstein's Atossa Therapeutics position peaked at $734K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on AllianceBernstein's 13F filing for Q2 2025, filed 14 Aug 2025.